Payment overview · 2025
General Payments
$962.11
46 reported records · 18 companies
Healthcare provider profile · identity verified
Assad U Darawal, MD
Allopathic & Osteopathic Physicians|Internal Medicine · INDIO, CA · NPI 1902877301
Verified facts
What the public records show
CMS Open Payments records show Assad U Darawal, MD received $962.11 in general payments during 2025 across 46 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Trelegy Ellipta, Xifaxan, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 374 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 323 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 820 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 323 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $329.91 | 34.3% | 12 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $122.00 | 12.7% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $81.45 | 8.5% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $71.44 | 7.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.05 | 4.8% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $43.59 | 4.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.70 | 4.0% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $35.97 | 3.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.12 | 3.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.55 | 3.1% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $21.52 | 2.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.22 | 1.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.20 | 1.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.04 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.00 | 1.8% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $14.27 | 1.5% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $13.59 | 1.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.49 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $962.11 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $260.27 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $212.71 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $143.07 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $122.00 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $81.45 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $71.44 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.05 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $45.84 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.70 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $35.97 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.12 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.55 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $27.30 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| Encore Normalized: encore |
Device | Philips North America LLC | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 323 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 224 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 374 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
224 | 39 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
374 | 75 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
323 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
820 | 127 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
72 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
323 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metformin Hcl | Metformin Hcl | 1150 | 268 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1137 | 310 |
| Gabapentin | Gabapentin | 1112 | 242 |
| Amlodipine Besylate | Amlodipine Besylate | 854 | 193 |
| Losartan Potassium | Losartan Potassium | 853 | 213 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 830 | 267 |
| Ozempic | Semaglutide | 820 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 740 | 171 |
| Metoprolol Succinate | Metoprolol Succinate | 683 | 143 |
| Pantoprazole Sodium | Pantoprazole Sodium | 681 | 164 |
| Omeprazole | Omeprazole | 614 | 165 |
| Lisinopril | Lisinopril | 599 | 144 |
| Ketoconazole | Ketoconazole | 507 | 97 |
| Escitalopram Oxalate | Escitalopram Oxalate | 456 | 106 |
| Trazodone Hcl | Trazodone Hcl | 446 | 99 |
| Ibuprofen | Ibuprofen | 418 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 410 | 105 |
| Meclizine Hcl | Meclizine Hcl | 406 | 87 |
| Meloxicam | Meloxicam | 401 | 119 |
| Duloxetine Hcl | Duloxetine Hcl | 376 | 99 |
| Jardiance | Empagliflozin | 374 | 75 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 370 | 71 |
| Hydralazine Hcl | Hydralazine Hcl | 358 | 80 |
| Baclofen | Baclofen | 330 | 78 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 323 | 69 |
| Eliquis | Apixaban | 323 | 58 |
| Diclofenac Sodium | Diclofenac Sodium | 316 | 46 |
| Spironolactone | Spironolactone | 293 | 73 |
| Furosemide | Furosemide | 290 | 74 |
| Carvedilol | Carvedilol | 280 | 67 |
| Potassium Chloride | Potassium Chloride | 278 | 55 |
| Invokana | Canagliflozin | 277 | 36 |
| Simvastatin | Simvastatin | 268 | 70 |
| Finasteride | Finasteride | 264 | 58 |
| Azithromycin | Azithromycin | 249 | 183 |
| Fluticasone Propionate | Fluticasone Propionate | 233 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 225 | 58 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 224 | 44 |
| Farxiga | Dapagliflozin Propanediol | 224 | 39 |
| Montelukast Sodium | Montelukast Sodium | 223 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 219 | 67 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 212 | 49 |
| Buspirone Hcl | Buspirone Hcl | 210 | 42 |
| Famotidine | Famotidine | 208 | 54 |
| Ezetimibe | Ezetimibe | 200 | 56 |
| Pioglitazone Hcl | Pioglitazone Hcl | 187 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 183 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 35 |
| Alendronate Sodium | Alendronate Sodium | 175 | 44 |
| Donepezil Hcl | Donepezil Hcl | 175 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 163 | 35 |
| Celecoxib | Celecoxib | 154 | 40 |
| Januvia | Sitagliptin Phosphate | 150 | 18 |
| Linzess | Linaclotide | 150 | 38 |
| Tradjenta | Linagliptin | 146 | 27 |
| Sertraline Hcl | Sertraline Hcl | 145 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 140 | 32 |
| Humalog Kwikpen U-100 | Insulin Lispro | 134 | 28 |
| Clobetasol Propionate | Clobetasol Propionate | 132 | 26 |
| Mounjaro | Tirzepatide | 129 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 124 | 26 |
| Levetiracetam | Levetiracetam | 123 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 122 | 33 |
| Tramadol Hcl | Tramadol Hcl | 122 | 32 |
| Chlorthalidone | Chlorthalidone | 120 | 24 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 120 | 28 |
| Alcohol Pads | Alcohol Antiseptic Pads | 117 | 12 |
| Azelastine Hcl | Azelastine Hcl | 117 | 28 |
| Entresto | Sacubitril/Valsartan | 117 | 14 |
| Topiramate | Topiramate | 117 | 23 |
| Mupirocin | Mupirocin | 116 | 35 |
| Xarelto | Rivaroxaban | 114 | 18 |
| Allopurinol | Allopurinol | 112 | 27 |
| Naproxen | Naproxen | 112 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 111 | 17 |
| Vascepa | Icosapent Ethyl | 111 | 20 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 109 | 20 |
| Terbinafine Hcl | Terbinafine Hcl | 108 | 32 |
| Methocarbamol | Methocarbamol | 102 | 39 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 101 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 100 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 99 | 32 |
| Metformin Hcl Er | Metformin Hcl | 97 | 21 |
| Ondansetron Odt | Ondansetron | 97 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 15 |
| Atenolol | Atenolol | 95 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 92 | 52 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 90 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 87 | 26 |
| Bumetanide | Bumetanide | 86 | 23 |
| Clonidine Hcl | Clonidine Hcl | 86 | 16 |
| Glipizide | Glipizide | 85 | 25 |
| Lorazepam | Lorazepam | 83 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 23 |
| Sumatriptan Succinate | Sumatriptan Succinate | 81 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 80 | 19 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 80 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 17 |
| Fenofibrate | Fenofibrate,micronized | 75 | 17 |
| Hydrocortisone | Hydrocortisone | 75 | 13 |
| Pregabalin | Pregabalin | 75 | 17 |
| Myrbetriq | Mirabegron | 74 | 12 |
| Nystatin | Nystatin | 73 | 19 |
| Rybelsus | Semaglutide | 72 | 17 |
| Lansoprazole | Lansoprazole | 71 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 71 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 70 | 15 |
| Creon | Lipase/Protease/Amylase | 69 | 17 |
| Nifedipine Er | Nifedipine | 68 | 19 |
| Nitroglycerin | Nitroglycerin | 68 | 22 |
| Dutasteride | Dutasteride | 65 | 16 |
| Alprazolam | Alprazolam | 64 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 64 | 14 |
| Warfarin Sodium | Warfarin Sodium | 63 | 11 |
| Fluconazole | Fluconazole | 62 | 41 |
| Icosapent Ethyl | Icosapent Ethyl | 62 | 18 |
| Mirtazapine | Mirtazapine | 61 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 59 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | suppressed |
| Trulicity | Dulaglutide | 59 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 58 | 14 |
| Clotrimazole | Clotrimazole | 57 | 15 |
| Memantine Hcl | Memantine Hcl | 56 | 15 |
| Benazepril Hcl | Benazepril Hcl | 53 | 14 |
| Dexamethasone | Dexamethasone | 53 | 47 |
| Sucralfate | Sucralfate | 53 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 52 | 19 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 51 | 38 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 51 | 23 |
| Primidone | Primidone | 51 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | suppressed |
| Kerendia | Finerenone | 50 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 49 | 16 |
| Clonidine | Clonidine | 48 | 11 |
| Latanoprost | Latanoprost | 48 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 48 | suppressed |
| Edarbi | Azilsartan Medoxomil | 46 | suppressed |
| Levofloxacin | Levofloxacin | 44 | 34 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 44 | 12 |
| Lidocaine | Lidocaine | 43 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 11 |
| Potassium Citrate Er | Potassium Citrate | 42 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 13 |
| Cyclosporine | Cyclosporine | 41 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 41 | 12 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 21 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Folic Acid | Folic Acid | 37 | suppressed |
| Novolog Flexpen | Insulin Aspart | 37 | 19 |
| Prolia | Denosumab | 37 | 24 |
| Ramipril | Ramipril | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 35 | suppressed |
| Sulfasalazine | Sulfasalazine | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 13 |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Misoprostol | Misoprostol | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Colchicine | Colchicine | 30 | suppressed |
| Etodolac | Etodolac | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Rivastigmine | Rivastigmine | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Cilostazol | Cilostazol | 29 | suppressed |
| Nystop | Nystatin | 29 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Mupirocin | Mupirocin Calcium | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Minoxidil | Minoxidil | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Acarbose | Acarbose | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 24 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Xifaxan | Rifaximin | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Ssd | Silver Sulfadiazine | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Ciclopirox | Ciclopirox | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Fluocinonide | Fluocinonide | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 19 | 11 |
| Verapamil Hcl | Verapamil Hcl | 19 | suppressed |
| Loperamide | Loperamide Hcl | 18 | 12 |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 13 |
| Prednisone | Prednisone | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Calcipotriene | Calcipotriene | 13 | suppressed |
| Comfort Ez Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $962.11 · 46 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, BREZTRI, CAMZYOS, ELIQUIS, Encore, FARXIGA, GVOKE HYPOPEN, JARDIANCE, Kerendia, NURTEC ODT, NUZYRA, REXULTI, SMARTVEST, TRELEGY ELLIPTA, VOQUEZNA, WAKIX, Wegovy, XHANCE, XIFAXAN, ZENPEP | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error